Oral manifestations after immune reconstitution in HIV patients on HAART

International Journal of STD and AIDS

Volumn 19, Issue 5, 2008, Pages 305-308

  Ortega, Karem L ^a,d   Ceballos Salobreña, Alejandro ^b   Gaitán Cepeda, Luis A ^c   Magalhães, Marina G ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b UNIVERSITY OF GRANADA   (Spain)

^c UNIVERSIDAD NACIONAL AUTÓNOMA DE MÉXICO   (Mexico)

^d Faculdade de Odontologia da Universidade   (Brazil)

Author keywords

AIDS; Antiretroviral therapy; HAART; HIV; Immune reconstitution; Oral manifestations; Salivary gland disease

Indexed keywords

PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; VIRUS RNA;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ARTICLE; CANDIDIASIS; CD4 LYMPHOCYTE COUNT; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME; MAJOR CLINICAL STUDY; MALE; MOUTH DISEASE; PAROTID ENLARGEMENT; PRIORITY JOURNAL; SEX DIFFERENCE; VIRUS LOAD;

ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4-CD8 RATIO; HIV INFECTIONS; HUMANS; IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME; IMMUNE TOLERANCE; INFLAMMATION; MOUTH DISEASES; OPPORTUNISTIC INFECTIONS; PREVALENCE;

EID: 44349117928     PISSN: 09564624     EISSN: None     Source Type: Journal    
DOI: 10.1258/ijsa.2007.007261     Document Type: Article

References (37)

1. Imamichi T. Action of anti-HIV drugs and resistance: reverse transcriptase inhibitors and protease inhibitors. Curr Pharm Des 2004;10:4039-53
2. Temesgen Z, Warnke D, Kasten MJ. Current status of antiretroviral therapy. Expert Opin Pharmacother 2006;7:1541-54
3. Chen LF, Hoy J, Lewin SR. Ten years of highly active antiretroviral therapy for HIV infection. Med J Aust 2007;186:146-51
4. Autran B, Carcelain G, Li TS, Blanc C, et al. Positive effects of combined antiretroviral therapy on CD4+ T cell homeostasis and function in advanced HIV disease. Science 1997;277:112-6
5. Brodt HR, Kamps BS, Gute P, Knupp B, Staszewski S, Helm EB. Changing incidence of AIDS-defining illnesses in the era of antiretroviral combination therapy. AIDS 1997;11:1731-8
6. Aguirre JM, Echebarria MA, Ocina E, Ribacoba L, Montejo M. Reduction of HIV-associated oral lesions after highly active antiretroviral therapy. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 1999;88:114-5
7. Pulvirenti JJ. Inpatient care of the HIV infected patient in the highly active antiretroviral therapy (HAART) era. Curr HIV Res 2005;3:133-45
8. Birnbaum W, Hodgson TA, Reichart PA, Sherson W, Nittayannanta SW, Axell TE. Prognostic significance of HIV-associated oral lesions and their relation to therapy. Oral Dis 2002;8:110-4
9. Ceballos-Salobrena A, Gaitan-Cepeda LA, Ceballos-Garcia L, Lezama-Del Valle D. Oral lesions in HIV/AIDS patients undergoing highly active antiretroviral treatment including protease inhibitors: a new face of oral AIDS? AIDS Patient Care STDs 2000;14:627-35
10. Hofman P, Nelson AM. The pathology induced by highly active antiretroviral therapy against human immunodeficiency virus: an update. Curr Med Chem 2006;13:3121-32
11. Greenspan D, Canchola AJ, MacPhail LA, Cheikh B, Greenspan JS. Effect of highly active antiretroviral therapy on frequency of oral warts. Lancet 2001;357:1411-2
12. Hodgson TA, Greenspan D, Greenspan JS. Oral lesions of HIV disease and HAART in industrialized countries. Adv Dent Res 2006;19:57-62
13. Schmidt-Westhausen AM, Priepke F, Bergmann FJ, Reichart PA. Decline in the rate of oral opportunistic infections following introduction of highly active antiretroviral therapy. J Oral Pathol Med 2000;29:336-41
14. Flint SR, Tappuni A, Leigh J, Schmidt-Westhausen AM, MacPhail L. Markers of immunodeficiency and mechanisms of HAART therapy on oral lesions. Adv Dent Res 2006;19:146-51
15. King MD, Reznik DA, O'Daniels CM, Larsen NM, Osterholt D, Blumberg HM. Human papillomavirus-associated oral warts among human immunodeficiency virus-seropositive patients in the era of highly active antiretroviral therapy: an emerging infection. Clin Infect Dis 2002;34:641-8
16. Lawn SD, Bekker LG, Miller RF. Immune reconstitution disease associated with mycobacterial infections in HIV-infected individuals receiving antiretrovirals. Lancet Infect Dis 2005;5:361-73
17. De Boer MG, Kroon FP, Kauffmann RH, Vriesendorp R, Zwinderman K, van Dissel JT. Immune restoration disease in HIV-infected individuals receiving highly active antiretroviral therapy: clinical and immunological characteristics. Neth J Med 2003;61:408-12
18. Shelburne SA, Hamill RJ. The immune reconstitution inflammatory syndrome. AIDS Rev 2003;5:67-79
19. Couppie P, Sarazin F, Clyti E, et al. Increased incidence of genital herpes after HAART initiation: a frequent presentation of immune reconstitution inflammatory syndrome (IRIS) in HIV-infected patients. AIDS Patient Care STDs 2006;20:143-5
20. EC Clearinghouse on Oral Problems related to HIV Infection and WHO Collaborating Centre on Oral Manifestations of the Immunodeficiency Virus. Classification and diagnostic criteria for oral lesions in HIV infection. J Oral Pathol Med 1993;22:289-91
21. Madec Y, Laureillard D, Pinoges L, et al. Response to highly active antiretroviral therapy among severely immuno-compromised HIV-infected patients in Cambodia. AIDS 2007;21:351-9
22. Manfredi R. HIV infection and advanced age emerging epidemiological, clinical and management issues. Ageing Res Rev 2004;3:31-54
23. Scully C, Diz Dios P. Orofacial effects of antiretroviral therapies. Oral Dis 2001;7:205-10
24. Park WB, Choe PG, Jo JH, et al. Immune reconstitution inflammatory syndrome in the first year after HAART: influence on long-term clinical outcome. AIDS 2006;20:2390-2
25. Ceballos-Salobrena A, Aguirre-Urizar JM, Bagan-Sebastian JV. Oral manifestations associated with human immunodeficiency virus infection in a Spanish population. J Oral Pathol Med 1996;25:523-6
26. Patton LL, McKaig R, Strauss R, Rogers D, Eron JJ Jr. Changing prevalence of oral manifestations of human immuno-deficiency virus in the era of protease inhibitor therapy. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2000;89:299-304
27. Nicolatou-Galitis O, Velegraki A, Paikos S, et al. Effect of PI-HAART on the prevalence of oral lesions in HIV-1 infected patients. A Greek study. Oral Dis 2004;10:145-50
28. Rangel AL, Coletta RD, Almeida OP, et al. Parotid mycobacteriosis is frequently caused by Mycobacterium tuberculosis in advanced AIDS. J Oral Pathol Med 2005;34:407-12
29. Namiq AL, Tollefson T, Fan F. Cryptococcal parotitis presenting as a cystic parotid mass: report of a case diagnosed by fine-needle aspiration cytology. Diagn Cytopathol 2005;33:36-8
30. Steele NP, Sampogna D, Sessions RB. Kaposi's sarcoma of an intraparotid lymph node leading to a diagnosis of HIV. Laryngoscope 2005;115:861-3
31. Pardo CA. Editorial comment: CD8+ lymphocytosis and DILS - a tale of split personality. AIDS Read 2002;12:410-1
32. Martinez E, Gatell J, Moran Y, et al. High incidence of herpes zoster in patients with AIDS soon after therapy with protease inhibitors. Clin Infect Dis 1998;27:1510-3
33. Wang AX, Li TS, Cao YZ, Han Y, Qiu ZF, Xie J. T-cell response of advanced AIDS patients after highly active antiretroviral therapy. Chin Med Sci J 2005;20:223-5
34. Miller RF, Isaacson PG, Hall-Craggs M, et al. Cerebral CD8+ lymphocytosis in HIV-1 infected patients with immune restoration induced by HAART. Acta Neuropathol 2004;108:17-23
35. Domingo P, Torres OH, Ris J, Vazquez G. Herpes zoster as an immune reconstitution disease after initiation of combination antiretroviral therapy in patients with human immunodeficiency virus type-1 infection. Am J Med 2001;110:605-9
36. De Simone JA, Pomerantz RJ, Babinchak TJ. Inflammatory reactions in HIV-1-infected persons after initiation of highly active antiretroviral therapy. Ann Intern Med 2000;133:447-54
37. French MA, Price P, Stone SF. Immune restoration disease after antiretroviral therapy. AIDS 2004;18:1615-27